The reagent kit is intended for non-invasive diagnostics of prostate cancer. The study determines the level of expression of the PCA3 gene, specific for prostate cancer, in relation to the level of the KLK3 gene, characteristic only for prostate tissue.
The kits can't be used for diagnostics of any pathology and are designed only for qualitative determination of the status of mutations to determine indications for targeted therapy.
Reagent kits cannot be used to diagnose any pathology and are intended only for qualitative determination of the NRAS gene mutation status to determine indications for targeted therapy.
Reagent kits cannot be used to diagnose any pathology and are intended only for qualitative determination of the EGFR gene mutation status to determine indications for targeted therapy.
The reagent kit is used in the examination of patients diagnosed with non-small cell lung cancer (NSCLC) to determine indications for targeted therapy with EGFR tyrosine kinase inhibitors and monitor response to them.
The testing kit is used when examining patients diagnosed with the metastatic melanoma stage III-IV in order to determine if they have indications for targeted therapy.